# UFP Technologies Inc: overview

UFPT · Nasdaq · CIK 914156 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ufpt.md) · [Financials](/companies/ufpt/financials.md) · [Filings](/companies/ufpt/filings.md) · [Insiders](/companies/ufpt/insiders.md)

Latest reported revenue: [$174.0m](/filings/0001628280-26-054428.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054428).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [145](/filings/0001628280-26-012816.md) | [144](/filings/0001628280-26-012816.md) | [148](/filings/0001628280-26-032825.md) | [151](/filings/0001628280-26-054428.md) | [155](/filings/0001628280-26-012816.md) | [149](/filings/0001628280-26-012816.md) | [154](/filings/0001628280-26-032825.md) | [174](/filings/0001628280-26-054428.md) |
| Gross margin | % | [28.6%](/filings/0001628280-26-012816.md) | [29.2%](/filings/0001628280-26-012816.md) | [28.5%](/filings/0001628280-26-032825.md) | [28.8%](/filings/0001628280-26-054428.md) | [27.7%](/filings/0001628280-26-012816.md) | [28.2%](/filings/0001628280-26-012816.md) | [28.8%](/filings/0001628280-26-032825.md) | [29.3%](/filings/0001628280-26-054428.md) |
| Operating margin | % | [17.1%](/filings/0001628280-25-050425.md) | [15.4% d](/filings/0001628280-26-012816.md) | [15.6%](/filings/0001628280-26-032825.md) | [16.1%](/filings/0001628280-26-054428.md) | [15.1%](/filings/0001628280-25-050425.md) | [14.4% d](/filings/0001628280-26-012816.md) | [15.2%](/filings/0001628280-26-032825.md) | [16.2%](/filings/0001628280-26-054428.md) |
| Net margin | % | [11.3%](/filings/0001628280-26-012816.md) | [11.4%](/filings/0001628280-26-012816.md) | [11.6%](/filings/0001628280-26-054428.md) | [11.4%](/filings/0001628280-26-054428.md) | [10.6%](/filings/0001628280-26-012816.md) | [11.8%](/filings/0001628280-26-012816.md) | [11.3%](/filings/0001628280-26-054428.md) | [12.0%](/filings/0001628280-26-054428.md) |
| Diluted EPS | $ per share | [2.11](/filings/0001628280-26-012816.md) | [2.10](/filings/0001628280-26-012816.md) | [2.21](/filings/0001628280-26-032825.md) | [2.21](/filings/0001628280-26-054428.md) | [2.11](/filings/0001628280-26-012816.md) | [2.25](/filings/0001628280-26-012816.md) | [2.24](/filings/0001628280-26-032825.md) | [2.68](/filings/0001628280-26-054428.md) |
| Free cash flow | $m | [17.7 d](/filings/0001628280-25-050425.md) | [21.4 d](/filings/0001628280-26-012816.md) | [11.0](/filings/0001628280-26-032825.md) | [22.5 d](/filings/0001628280-26-054428.md) | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [206](/filings/0001171843-24-001078.md) | [354](/filings/0001171843-25-001192.md) | [400](/filings/0001628280-26-012816.md) | [504](/filings/0001628280-26-012816.md) | [603](/filings/0001628280-26-012816.md) |
| Gross margin | % | [24.8%](/filings/0001171843-24-001078.md) | [25.5%](/filings/0001171843-25-001192.md) | [28.1%](/filings/0001628280-26-012816.md) | [29.1%](/filings/0001628280-26-012816.md) | [28.3%](/filings/0001628280-26-012816.md) |
| Operating margin | % | [10.3%](/filings/0001171843-24-001078.md) | [15.7%](/filings/0001171843-25-001192.md) | [14.4%](/filings/0001628280-26-012816.md) | [16.0%](/filings/0001628280-26-012816.md) | [15.3%](/filings/0001628280-26-012816.md) |
| Net margin | % | [7.7%](/filings/0001171843-24-001078.md) | [11.8%](/filings/0001171843-25-001192.md) | [11.2%](/filings/0001628280-26-012816.md) | [11.7%](/filings/0001628280-26-012816.md) | [11.3%](/filings/0001628280-26-012816.md) |
| Diluted EPS | $ per share | [2.09](/filings/0001171843-24-001078.md) | [5.45](/filings/0001171843-25-001192.md) | [5.83](/filings/0001628280-26-012816.md) | [7.58](/filings/0001628280-26-012816.md) | [8.75](/filings/0001628280-26-012816.md) |
| Free cash flow | $m | [8.9](/filings/0001171843-24-001078.md) | [4.0](/filings/0001171843-25-001192.md) | [30.8](/filings/0001628280-26-012816.md) | [56.9](/filings/0001628280-26-012816.md) | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ufpt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $302.6m | 1,141,410 |  | Added +44,227 |
| [CONGRESS ASSET MANAGEMENT CO](/funds/897378.md) | 2026-06-30 | $182.3m | 687,439 |  | Added +164,001 |
| [WASATCH ADVISORS LP](/funds/814133.md) | 2026-06-30 | $181.2m | 683,262 |  | Reduced −94,051 |
| [NEUBERGER BERMAN GROUP LLC](/funds/1465109.md) | 2026-06-30 | $142.4m | 537,038 |  | Added +236,445 |
| [Boston Trust Walden Corp](/funds/1534866.md) | 2026-06-30 | $89.2m | 336,278 |  | Added +19,206 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $87.4m | 329,623 |  | Added +2,898 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $82.9m | 312,811 |  | Added +9,498 |
| [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $74.2m | 279,976 |  | Added +154,116 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $67.5m | 254,740 |  | Added +81,000 |
| [MASSACHUSETTS FINANCIAL SERVICES CO /MA/](/funds/912938.md) | 2026-06-30 | $59.2m | 223,474 |  | Reduced −3,829 |

## Recent filings

[All 1,107 filings](/companies/ufpt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-24 | 14:09 ET | [8-K](/filings/0001628280-26-058536.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-058536 |
| 2026-08-06 | 20:50 ET | [10-Q](/filings/0001628280-26-054428.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054428 |
| 2026-08-03 | 20:12 ET | [8-K](/filings/0001628280-26-051846.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-051846 |
| 2026-06-10 | 20:02 ET | [8-K](/filings/0001628280-26-042165.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-042165 |
| 2026-06-08 | 20:44 ET | [8-K](/filings/0001628280-26-041647.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-041647 |
| 2026-06-05 | 16:37 ET | [8-K](/filings/0001628280-26-041108.md) | 5.07 Shareholder vote results | 0001628280-26-041108 |
| 2026-05-26 | 20:17 ET | [8-K](/filings/0001628280-26-038097.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-038097 |
| 2026-05-08 | 20:03 ET | [10-Q](/filings/0001628280-26-032825.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032825 |
| 2026-05-04 | 20:56 ET | [8-K](/filings/0001628280-26-029906.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-029906 |
| 2026-04-30 | 16:40 ET | [DEF 14A](/filings/0001628280-26-028710.md) | Proxy statement, period 2026-06-04 | 0001628280-26-028710 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012816.md), filed Feb 27, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/b4f3449b-44f4-4c14-80ea-4ae865f28175)

## About the filer

- CIK: 914156
- Tickers: UFPT
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.